<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04808739</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-ADA-2020-32</org_study_id>
    <nct_id>NCT04808739</nct_id>
  </id_info>
  <brief_title>Adalimumab Biosimilar in Clinical Practice</brief_title>
  <official_title>Retrospective Observational Study to Analyze the Effectiveness of Adalimumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational, retrospective, multicenter, and descriptive study of patients&#xD;
      treated with adalimumab biosimilar for psoriasis, according to clinical practice.&#xD;
&#xD;
      Existing data will be collected from the Dermatology Services database of the hospitals&#xD;
      participating in the study, from the medical histories of all treated patients who meet the&#xD;
      inclusion criteria and sign informed consent.&#xD;
&#xD;
      The aim of the study is to determine the effectiveness of the different adalimumab&#xD;
      biosimilars in clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adalimumab is indicated for the treatment of moderate to severe chronic plaque psoriasis in&#xD;
      adult patients who are candidates for systemic treatment. There are currently several&#xD;
      biosimilar drugs (Amgevita, Imraldi, Hyrimoz, Idacio, Hulio,…) in addition to the reference&#xD;
      product (Humira).&#xD;
&#xD;
      The reduction in the cost of production of biosimilar drugs with respect to reference&#xD;
      products has led to their replacement by biosimilar drugs in patients initiating biological&#xD;
      therapy, but some centers are also switching to adalimumab biosimilar in patients who are&#xD;
      controlled with original adalimumab (Humira).&#xD;
&#xD;
      There are no actual clinical efficacy / safety data in our setting on the use of adalimumab&#xD;
      biosimilars.&#xD;
&#xD;
      There is also no evidence of maintenance response in patients who are switched from&#xD;
      adalimumab (Humira) to biosimilar adalimumab in clinical practice.&#xD;
&#xD;
      This retrospective study will collect demographic and disease data of the psoriasis patient&#xD;
      treated with the different biosimilars of adalimumab, as well as their comorbidities,&#xD;
      response to treatment, and safety. In this way, data will be available in usual clinical&#xD;
      practice to improve the management of the patient with psoriasis treated with biosimilar&#xD;
      drugs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Actual">February 28, 2021</completion_date>
  <primary_completion_date type="Actual">February 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Median time of survival (months) of adalimumab biosimilar in clinical practice</measure>
    <time_frame>1 year</time_frame>
    <description>Median time of survival (months) of patients under treatment with adalimumab biosimilar in clinical practice</description>
  </primary_outcome>
  <enrollment type="Actual">604</enrollment>
  <condition>Psoriasis</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Analysis of survival of adalimumab biosimilar in clinical practice</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with moderate-severe psoriasis vulgaris who are candidates for systemic treatment&#xD;
        undergoing adalimumab treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of both sexes who have received treatment with adalimumab and who have signed&#xD;
             an informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to participate.&#xD;
&#xD;
          -  Any other cause of exclusion based on clinical criteria and the technical data sheet&#xD;
             of the drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lluís Puig, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Khandpur S, Sondhi P, Taneja N, Sharma P, Das D, Sharma A, Sreenivas V. Evaluation of adalimumab biosimilar in treatment of psoriatic arthritis with concomitant moderate to severe chronic plaque psoriasis: An open-labeled, prospective, pilot case series. J Am Acad Dermatol. 2020 Jul;83(1):248-251. doi: 10.1016/j.jaad.2019.12.071. Epub 2020 Feb 19.</citation>
    <PMID>32087993</PMID>
  </reference>
  <reference>
    <citation>Reynolds KA, Pithadia DJ, Lee EB, Liao W, Wu JJ. Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis. Am J Clin Dermatol. 2020 Aug;21(4):483-491. doi: 10.1007/s40257-020-00507-1. Review.</citation>
    <PMID>32048187</PMID>
  </reference>
  <reference>
    <citation>Hercogová J, Papp KA, Chyrok V, Ullmann M, Vlachos P, Edwards CJ. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2020 Feb;182(2):316-326. doi: 10.1111/bjd.18220. Epub 2019 Sep 26.</citation>
    <PMID>31206593</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will be collected and data analysed in Institut de Recerca Hospital de la Santa Creu i Sant Pau</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

